British Columbia Expands Use of Biosimilars to Explore Treatment Options

 British Columbia Expands Use of Biosimilars to Explore Treatment Options

British Columbia Expands Use of Biosimilars to Explore Treatment Options

Shots:

  • BC decided to switch from reference product to biosimilars within 6 months, for patients suffering from diabetes, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis
  • Post Nov 25,2019 PharmaCare, a publicly funded national drug coverage program will no longer be providing coverage for the biologic products excluding some exceptional cases and patients receiving Enbrel, Remicade and Lantus will switch to Eticovo, Renflexis and Basaglar respectively
  • BC plans to save $96.6B in first three years and the decision is in practice with the listing of Jardiance and Taltz drug for diabetes and psoriatic arthritis respectively

Click here to read full press release/ article | Ref: British Columbia | Image: LinkedIn

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post